Opthea shares target raised on trial progress, page-11

Personally, I think OPT is a better bet than MSB. We could well see a capital raising (CR) or we might secure funding through a partnership with a major global company. After grappling with the knowledge that a dilution event is very likely to occur in the next 2-3 months, I decided anyway to invest the limit of my 'at risk' capital allocation now. It would certainly hurt if it hit 0 cents, so while accepting the risk, I expect I may take some money off the table in 2024 or early 2025, depending on how things progress